Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,871 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro G Jr, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, Raja R, Naicker K, Scheuring U, Walker J, Mann H, Chand V, Mok T; NEPTUNE Investigators. de Castro G Jr, et al. Among authors: walker j. J Thorac Oncol. 2023 Jan;18(1):106-119. doi: 10.1016/j.jtho.2022.09.223. Epub 2022 Oct 12. J Thorac Oncol. 2023. PMID: 36240972 Free article. Clinical Trial.
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Boothman AM, Scott M, Ratcliffe M, Whiteley J, Dennis PA, Wadsworth C, Sharpe A, Rizvi NA, Garassino MC, Walker J. Boothman AM, et al. Among authors: walker j. J Thorac Oncol. 2019 Aug;14(8):1390-1399. doi: 10.1016/j.jtho.2019.04.025. Epub 2019 May 4. J Thorac Oncol. 2019. PMID: 31063864 Free article.
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Wildsmith S, Li W, Wu S, Stewart R, Morsli N, Raja R, Zhang Q, Ye J, He P, Shetty J, Yovine A, Holoweckyj N, Real K, Walker J, Wrona M, de Los Reyes M, Barker C, Whiteley J, Haddad R, Licitra L, Ferris R, Fayette J, Zandberg DP, Siu LL, Mesía R. Wildsmith S, et al. Among authors: walker j. Clin Cancer Res. 2023 Jun 1;29(11):2066-2074. doi: 10.1158/1078-0432.CCR-22-2765. Clin Cancer Res. 2023. PMID: 36806911 Free PMC article. Clinical Trial.
Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.
Hong TH, Hwang S, Dasgupta A, Abbosh C, Hung T, Bredno J, Walker J, Shi X, Milenkova T, Horn L, Choi JY, Lee HY, Cho JH, Choi YS, Shim YM, Chai S, Rhodes K, Roychowdhury-Saha M, Hodgson D, Kim HK, Ahn MJ. Hong TH, et al. Among authors: walker j. J Thorac Oncol. 2024 Nov;19(11):1512-1524. doi: 10.1016/j.jtho.2024.07.002. Epub 2024 Jul 9. J Thorac Oncol. 2024. PMID: 38992468
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM. Hirsch FR, et al. Among authors: walker j. J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29. J Thorac Oncol. 2017. PMID: 27913228 Free article. Clinical Trial.
Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.
Dalvi T, Nørgaard M, Fryzek JP, Movva N, Pedersen L, Pham Hansen H, Walker J, Midha A, Shire N, Boothman AM, Rigas J, Mellemgaard A, Rasmussen TR, Hamilton-Dutoit S, Cronin-Fenton D. Dalvi T, et al. Among authors: walker j. PLoS One. 2023 Apr 11;18(4):e0284037. doi: 10.1371/journal.pone.0284037. eCollection 2023. PLoS One. 2023. PMID: 37040387 Free PMC article.
8,871 results